BEAM THERAPEUTICS INC.

BEAM

CIK 0001745999 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$114M
↑+279.5% +$84Mvs FY2024 (Q4)
Operating Income
$9M
Net Income
$9M
Gross Profit
$114M
↑+279.5% +$84Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    0ROIC -30.7% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 13.09 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.11x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +279.5% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -1307.6% · trend -427.0pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$15M
investment in PP&E
Stock-based comp (TTM)
$94M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$1.48B
everything owned
Total liabilities
$243M
everything owed
Stockholders' equity
$1.24B
shareholder claim

Recent performance · 28 quarters

Revenue↑+279.5% +$84M
$114M
Net Income
$33M
Free Cash Flow↓-25.7% -$764K
$-4M
Operating Margin↓-561.2pts
-1307.6%

Drill down